Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GS102
- Development stage
- Preclinical
- Lead developer
- Jiangsu Genscend Biopharmaceutical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
GS102 is a preclinical monoclonal antibody biosimilar of risankizumab (Skyrizi) being developed by Jiangsu Genscend Biopharmaceutical for the treatment of autoimmune diseases. It selectively targets the p19 subunit of interleukin-23 (IL-23), thereby preventing IL-23 from binding to its receptor and blocking downstream inflammatory signaling pathways. The candidate is currently in preclinical/IND-enabling development, with an IND filing projected for Q2 2027 and a BLA filing planned for Q1 2030.
- Other names
- Risankizumab biosimilar
02
Targets
FcγR (Low affinity immunoglobulin gamma Fc region receptor II-c)IL23R (Interleukin-23 Receptor)IL23A (Interleukin-23 p19 Subunit)FCGRT (Neonatal crystallizable fragment receptor)
Beyond the preview
Go deeper on GS102.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GS102.